Related Experiment Video

Updated: Oct 8, 2025

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.3K

Is a BTKi or BCL2i preferable for first "novel" therapy in CLL? The case for BTKis

Elizabeth A Brem1, Susan O'Brien1

  • 1Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, CA.

Blood Advances
|December 29, 2021
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

21.6K
Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment
11:11

Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment

Published on: January 24, 2020

11.1K

Related Experiment Videos

Last Updated: Oct 8, 2025

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.3K
Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

21.6K
Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment
11:11

Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment

Published on: January 24, 2020

11.1K

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K

Articles linked to this work by shared authors, journal, and citation graph.

Upfront Management of Blastoid Variant Mantle Cell Lymphoma: Making the Case for 2nd/3rd-Generation Bruton Tyrosine Kinase Inhibitor-Based Therapies.

Cancer medicine·2024

Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b/2 study.

Blood advances·2023

Anakinra versus etoposide-based therapy added to high-dose steroids for the treatment of secondary hemophagocytic lymphohistiocytosis.

European journal of haematology·2023

Hemophagocytic lymphohistiocytosis in the setting of HELLP Syndrome.

Clinical case reports·2018

Functional Differences between IgM and IgD Signaling in Chronic Lymphocytic Leukemia.

Journal of immunology (Baltimore, Md. : 1950)·2016

Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial.

British journal of haematology·2016

Murine model for Congenital Dyserythropoietic Anemia Type I.

Blood advances·2026

Mast cells enhance venous thrombus stability and lung fibrin deposition in murine sepsis.

Blood advances·2026

Teclistamab and Daratumumab Immune-Based Doublet Therapy for Relapsed/Refractory Multiple Myeloma: the TRIMM-2 Study.

Blood advances·2026

Anti-PF4 antibodies trigger a faster and stronger platelet procoagulant response than anti-heparin/PF4 antibodies.

Blood advances·2026

PTPN2 Deletion Enhances CAR-T Effector Function and CNS Trafficking in a Non-Human Primate Model.

Blood advances·2026

Jagunal homolog 1 safeguards neutrophil immune function by preserving protein sialylation during differentiation.

Blood advances·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us